Establishment of a High-risk MDS/AML Cell Line YCU-AML1 and its Xenograft Model Harboring t(3;3) and Monosomy 7-Reference-Cited by-同舟云学术

Establishment of a High-risk MDS/AML Cell Line YCU-AML1 and its Xenograft Model Harboring t(3;3) and Monosomy 7

Published:2020-09-17 Issue:5 Volume:4 Page:e469
ISSN:2572-9241
Container-title:HemaSphere
language:en
Short-container-title:

Author:

Kunimoto Hiroyoshi,Fukuchi Yumi,Murakami Koichi,Ikeda Junji,Teranaka Hiroshi,Kato Ikuma,Miyazaki Takuya,Enaka Makiko,Mitsuhashi Takayuki,Yamazaki Etsuko,Kameyama Kaori,Murata Mitsuru,Okamoto Shinichiro,Nakajima Hideaki

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Hematology

Reference30 articles.

1. Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system;Weinberg;Blood.,2009

2. Japan Adult Leukemia Study Group. Cytogenetic heterogeneity of acute myeloid leukaemia (AML) with trilineage dysplasia: Japan Adult Leukaemia Study Group-AML 92 study;Miyazaki;Br J Haematol.,2003

3. Clinical molecular and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia;Lugthart;J Clin Oncol.,2010

4. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study;Rogers;Haematologica.,2014

5. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia;N Engl J Med.,2013

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Progress in construction of mouse models to investigate the pathogenesis and immune therapy of human hematological malignancy;Frontiers in Immunology;2023-08-14

2. Cytogenetics analysis as the central point of genetic testing in acute myeloid leukemia (AML): a laboratory perspective for clinical applications;Clinical and Experimental Medicine;2022-10-13

3. Aberrant EVI1 splicing contributes to EVI1-rearranged leukemia;Blood;2022-08-25